Los Angeles Capital Management
APGE

Los Angeles Capital Management’s Apogee Therapeutics APGE Stock Holding History

Los Angeles Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Hold
136
– – ﹤0.01% 1812
2026
Q1 		$11.4K Sell
136
-354
-72% -$25.7K ﹤0.01% 1912
2025
Q4 		$27.5K Buy
+490
New +$30.9K ﹤0.01% 1772
2024
Q4 		– Sell
-6,534
Closed -$384K – 1110
2024
Q3 		$384K Sell
6,534
-370
-5% -$17.7K ﹤0.01% 933
2024
Q2 		$272K Buy
+6,904
New +$335K ﹤0.01% 1047

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Los Angeles Capital Management's APGE Position: Q2 2026 in Review

Los Angeles Capital Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 136 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1812.

Los Angeles Capital Management first reported a position in APGE in Q2 2024 and has held it in 5 quarters since. The position peaked at $384K in Q3 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Los Angeles Capital Management held 136 shares of Apogee Therapeutics worth $18.1K as of Q2 2026.
  • Los Angeles Capital Management left its Apogee Therapeutics share count unchanged in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1812 holding.
  • Los Angeles Capital Management first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Apogee Therapeutics position peaked at $384K in Q3 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.